HHS Secretary Robert F. Kennedy Jr, is a well-known vaccine critic, but it is way past time for human health to be put on a ...

KNOWING where to invest your cash is difficult as there are thousands of companies to choose from. That’s why Holly Mead, a ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the ...

FTSE 100 pushes higher as US rate cut bets build - The FTSE 100 index closed up 17.42 points, 0.2%, at 9,165.23.

In late April, the FDA notified SCYNEXIS that the clinical hold on ibrexafungerp had been lifted and concluded that the Phase 3 MARIO study could resume. The MARIO study is a Phase 3 trial evaluating ...

The S&P 500 rose 1.1% to peak at 6,445 while the tech-focused Nasdaq Composite surged 1.4% to a new record. The Dow Jones ...

In exchange, Hengrui will receive $500m in upfront fees and will be eligible for approximately $12bn in development, ...

The global Musculoskeletal Oncology Therapeutics Market is projected to grow from USD 2.2 billion in 2025 to USD 3.3 billion ...

A powerful wave of optimism continued to wash over global markets on Wednesday, propelling European equities higher as ...

President Donald Trump has called on 17 pharmaceutical companies to implement most-favored-nation drug pricing in the next 60 days.

In addition to Barclays, Sanofi also received a Buy from J.P. Morgan’s Richard Vosser in a report issued on August 8. However, on August 5, Deutsche Bank maintained a Hold rating on Sanofi (Other OTC: ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero ...